Search
SAB Biotherapeutics Inc
SABSAdd to Watchlist
3.130USD
+0.100+3.30%
Market hours 11/09, 11:43（ET）
284.80MMarket Cap
7.32P/E TTM
SAB Biotherapeutics Inc (SABS) Stock Price Target & Forecast
Analyst Rating
Based on 11 analysts giving stock ratings to SAB Biotherapeutics Inc in the past month.
Buy
5 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
11.636USD+247.35%
SABS Analyst Recommendation Trends
In the current month, SABS has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SABS average Analyst price target in the last month is 11.636.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
5
5
5
5
5
3
3
3
6
6
6
6
5
5
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11
11
11
11
10
8
8
8
SABS Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
IQVIA Holdings Inc
IQV
8
13
1
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, SABS EPS is projected to reach -0.256 in FY2026Q4, following reported EPS of -0.239 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.23
-0.29
-0.27
-0.26
-0.22
Actual
-0.35
-0.28
-0.24
--
--
Surprise
-54.29%
+2.55%
+11.42%
--
--
FAQs
What is SAB Biotherapeutics Inc's price target?
Analysts forecast that SAB Biotherapeutics Inc's price target is USD 11.64, with the highest forecast at USD 16.00 and the lowest forecast at USD 6.00.
How have SAB Biotherapeutics IncSABS's recent earnings per share performed?
The market expectation was USD -0.24, while SAB Biotherapeutics IncSABS's earnings per share (EPS) for the previous quarter was USD -0.28. EPS for the next quarter is expected at USD -0.26.
What is the analyst rating for SAB Biotherapeutics Inc?
Based on the ratings of SAB Biotherapeutics Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.